• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»botulinum neurotoxin

Curi Bio and Battelle commercialise human NMJ assay as GLP-ready alternative to mouse bioassay for botulinum toxin testing

By Pallavi Madhiraju on March 21, 2026   Medical Devices & Diagnostics  

Curi Bio and Battelle commercialise human NMJ assay as GLP-ready alternative to mouse bioassay for botulinum toxin testing

Curi Bio and Battelle partner to commercialise a human NMJ assay for botulinum toxin potency testing. What this changes for NAM adoption and the mouse bioassay. Read more.

Merz Therapeutics files XEOMIN pediatric spasticity indication with EMA following Phase 3 success

By Pallavi Madhiraju on January 26, 2026   Medical Devices & Diagnostics  

Merz Therapeutics files XEOMIN pediatric spasticity indication with EMA following Phase 3 success

Merz Therapeutics files EMA application to expand XEOMIN for pediatric spasticity. Find out how this could shift the treatment landscape for cerebral palsy.

Recent Posts

  • AACR 2026: SAGA Diagnostics pushes Pathlight MRD deeper into metastatic breast and ovarian cancer
  • Agenus AACR 2026 data show immune reprogramming signal in PD-1 refractory gastroesophageal cancer
  • AACR 2026: Can Zai Lab’s zocilurtatug pelitecan change the treatment picture for small cell lung cancer brain metastases?
  • How JANX014 expands Janux Therapeutics’ tumor-activated platform strategy in prostate cancer immunotherapy
  • What Medicus Pharma Ltd.’s SkinJect application signals for Hedgehog pathway-driven cancers
  • Why Bioxodes’ adaptive trial strategy could accelerate approval timelines in stroke therapeutics
  • What Kura Oncology’s latest data reveals about resistance biology in kidney cancer
  • Can Fate Therapeutics, Inc. solve the conditioning chemotherapy problem in CAR T?
  • Could Ampligen become a late-stage pancreatic cancer breakthrough after AIM ImmunoTech’s latest clinical push?
  • What the new J-code means for Glaukos’ Epioxa launch and the future of keratoconus reimbursement
  • Molgramostim review pushed to November: what Savara’s FDA delay means for autoimmune PAP
  • What SurGenTec’s TiLink navigation clearance means for surgeons using minimally invasive SI joint fusion systems
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes